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Summary
Background: In previous studies, nitazoxanide has demonstrated a cytoprotective effect against
rotavirus, reducing the duration of diarrhea in comparison to placebo.We designed a randomized,
single-blind, controlled trial in order to assess the effectiveness of nitazoxanide and probiotics in
comparison with a control group.
Methods: Seventy-five children aged from 28 days to 24 months, with rotavirus diarrhea, were
randomly assigned to receive either oral nitazoxanide (15 mg/kg/day) twice a day for three days, a
combination of oral probiotics, 1 g twice a day for five days, or only oral or systemic rehydration
solutions. The duration of diarrhea and of hospitalizationwere the primary outcomemeasures, and
daily stool frequency, vomiting, and feverwere someof the secondary outcomemeasures analyzed.
Results: The median duration of hospitalization was significantly shorter (p = 0.017) in patients
who received nitazoxanide (81 h) and probiotics (72 h) compared to patients who received oral
rehydration solution alone (108 h). Similarly, the median duration of diarrhea was significantly
reduced (p = 0.009) in childrenwho received nitazoxanide (54 h) and probiotics (48 h) compared to
the control group (79 h).
Conclusions: Treatment with nitazoxanide and probiotics is effective in the management of
children with acute rotavirus diarrhea. Small differences in favor of nitazoxanide were found in
comparison with probiotics. Nitazoxanide is an important treatment option for rotavirus diarrhea.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Tel.: +591 4 4404194.
E-mail address: carteran79@hotmail.com (C.G. Teran).
1201-9712/$36.00 # 2008 International Society for Infectious Diseases.
doi:10.1016/j.ijid.2008.09.014Introduction
Since their discovery in the 1970s, the human rotaviruses have
been recognized as the most common infectious agent asso-
ciated with diarrhea in the pediatric age group worldwide.1 InPublished by Elsevier Ltd. All rights reserved.
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of dehydration associated with infectious diarrhea cases
admitted to hospital. Globally, rotavirus is the cause of about
440 000 diarrheal deaths every year. An estimated 1205 chil-
dren die from rotavirus disease each day, and around 80% of
these deaths occur in children in the poorest countries.2
The treatment of rotavirus diarrhea has remained rela-
tively unchanged over the last 35 years. Oral rehydration,
breastfeeding, and early refeeding are still the most impor-
tant tools in the management of children and infants with
acute gastroenteritis and rotavirus diarrhea.
Clinical trials have demonstrated the effectiveness of
probiotics in the treatment and prevention of acute diar-
rhea, decreasing the severity and duration of rotavirus
infections in children as well as diarrhea in adults. Well-
controlled clinical studies have shown that probiotics such as
Lactobacillus rhamnosus GG, Lactobacillus reuteri, Lacto-
bacillus casei, and Saccharomyces boulardii can safely be
used in the nutritional management of patients with infec-
tious diarrhea. According to these analyses, probiotics
reduce the duration of diarrhea by 0.6—0.7 days and reduce
stool frequency.3,4 The effect of probiotic therapy in rota-
virus infectious diarrhea has been explained by a reduction
in the duration of rotavirus shedding, normalization of gut
permeability after rotavirus infection, and by an increase in
the expression of mucin and IgA-secreting cells working
against rotavirus.5
Nitazoxanide is a new nitrothiazole benzamide com-
pound notable for its activity in treating both intestinal
protozoal and helminthic infections with a low range of
minor adverse effects.6 Nitazoxanide has been reported to
be effective against a broad range of parasites, including
Giardia lamblia, Entamoeba histolytica, Cryptosporidium
parvum, and Ascaris lumbricoides.7 The antiprotozoal
activity of nitazoxanide is believed to be due to interfer-
ence with the pyruvate ferredoxin oxidoreductase (PFOR)
enzyme-dependent electron transfer reaction, which is
essential to anaerobic energy metabolism.8 The US Food
and Drug Administration (FDA) approved the oral suspension
of nitazoxanide for the treatment of diarrhea caused by
Cryptosporidium species and Giardia lamblia in pediatric
patients in December 2002.
The first research on the antiviral effects of nitazoxanide
was published in 2006. Tizoxanide (the active metabolite of
nitazoxanide) showed a cytoprotective effect in rotavirus-
infected cells in studies carried out in vitro. Double-blind,
placebo-controlled trials in children and adults have shown a
significant reduction in the median duration of diarrhea from
the first dose of nitazoxanide administration in comparison
with placebo.9,10
Methods
Study design and population
A prospective, randomized, single-blind, controlled trial was
designed in order to assess the effectiveness of nitazoxanide
in comparison with a mixed probiotic preparation and a
control group. The study was conducted at the Pediatric
Center Albina Patin˜o, a reference hospital in the city of
Cochabamba, Bolivia, from August 2007 to February 2008.The study protocol was approved by the hospital ethics
committee and the investigation board of the Pediatric
Center Albina Patin˜o. Consent was obtained from parents
or caretakers of all the children who met the inclusion
criteria for the study before commencing the study protocol.
Male and female infants, aged from 28 days to 24 months,
with a history of acute watery diarrhea positive for rotavirus
of less than 72 h duration and a moderate to severe degree of
dehydration, who were brought to the gastroenterology or
infectious disease department, were eligible for inclusion in
the study. Patients with severe malnutrition, systemic infec-
tions requiring antibiotic therapy, and with the presence of
severe chronic disease were excluded. The identification of
another enteric pathogen or mixed enteric infections and
ingestion of antibiotics, probiotics, or nitazoxanide in the last
3 weeks before admission, were also exclusion criteria.
In order to detect an average difference of 24 h between
nitazoxanide, probiotics, and the control group, we assumed
a standard deviation for the duration of diarrhea in the
control group of 30 h. To obtain the required power of 86%
and a significance level of 5% (error = 0.05, two-tailed test),
we needed 25 participants in each group.
Procedures
Parents or caretakers of the enrolled patients were not
informed about the preparation assigned to their children.
Nursing staff were responsible for the administration of the
solution. They were trained to prepare the solutions assigned
in similar containers to mask the nature of the product.
Patients were randomly assigned from a computerized admis-
sions list to one of the three different treatment groups
described below.
The first group received nitazoxanide (100 mg/5 ml)
solution at a dose of 15 mg/kg/day divided into two doses,
for three days. The second group received a mixed probiotic
preparation (Lactobacillus acidophilus, Lactobacillus
rhamnosus, Bifidobacterium longum, Saccharomyces bou-
lardii), 1.25 billion mixed cells per gram at a dose of 1 g
twice a day for at least 5 days. The third group was assigned
to receive oral or systemic rehydration solutions alone,
according to the evolution of diarrhea. It should be noted
that the nitazoxanide and probiotic groups also received
oral or systemic hydration according to the disease evolu-
tion and that the mean duration of administration of pro-
biotics was 4.2 days.
All the patients were fed according to their age. Those
aged less than 6 months were breastfed or received milk
formula appropriate for their age. Patients aged more than 6
months received milk formula or breast milk and solid food
based on chicken meal, potatoes, rice, carrots, and vegeta-
ble oil. No patient included in the study was administered
delactosed milk, supplemental vitamins, or zinc.
Microscopic stool examination and stool culture for
common enteropathogenic bacteria were performed in
order to rule out other causative agents of diarrhea.
The test used for the diagnosis of rotavirus and adenovirus
was based on the immunochromatographic test RIDA Quick
Rotavirus/Adenovirus Combi (R-Biopharm AG, Darmstadt,
Germany).
The nursing staff were in charge of recording the number
and consistency of stools. Fever, vomiting, and other prob-
Figure 1 Study flow chart.
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designed charts. Once the patients were discharged from
hospital, one follow-up consultation was conducted within
the following 48 to 72 h; the recurrence of diarrhea was
considered a further exclusion criterion.
Definitions
Acute diarrhea was defined as the presence of at least
three stools of liquid consistency per day. Time of hospi-
talization was considered the interval of time from admis-
sion until discharge. Duration of diarrhea or resolution of
diarrhea was defined as the time from admission until the
presence of the first soft stool for at least 24 h. Hospital
discharge was considered 24 h after resolution of diarrhea
was achieved.
The time from the first dose to the presence of the first
soft stool was also considered as a primary endpoint for the
comparison between probiotic and nitazoxanide. The pre-
sence of fever was calculated from admission until the last
peak during hospitalization.
The nutrition status of the patient was classified according
to Z score and the World Health Organization tables for
developing countries. Patients with a Z score of 3 or lower
were considered to have severe malnutrition and were
excluded from the study.
The clinical scale of Fortin and Parent was employed to
classify the degree of dehydration into mild, moderate, or
severe.
Statistical analysis
All data were entered into the JMP 6.0 statistical discovery
program (SAS Institute Inc., Cary, NC, USA) for the analysis of
mean, median, interquartile range (IQR), and standard
deviation. Statistical significance was calculated using the
Chi-square test for proportions, the non-parametric Wilcoxontest for medians, and the Student’s t-test for means. The
Wilcoxon/Kruskal—Wallis test was used for comparison of
three groups of means. An additional survival analysis was
performed to compare the effectiveness of nitazoxanide and
probiotics according to the Wilcoxon test.
Results
A total of 147 patients with acute diarrhea secondary to
rotavirus infection were admitted to the hospital between
August 2007 and February 2008. Only 90 children were
eligible to complete the study protocol. In most cases,
exclusion was due to age, additional infectious disease,
previous ingestion of probiotics, and severe malnourish-
ment. Fifteen patients from the eligible group were
excluded due to the finding of a second causative agent
of diarrhea, three with G. lamblia, six with E. histolytica,
one with Shigella flexneri, and five with adenovirus
(Figure 1).
Clinical and demographic characteristics of the study
patients are summarized in Tables 1 and 2. A statistically
significant difference in the duration of hospitalization was
observed ( p = 0.017) for the nitazoxanide group (81 h; IQR
61.5—97) and the probiotics group (72 h; IQR 56—101) in
comparison to the control group (108 h; IQR 77—119). The
duration of diarrhea was also significantly reduced
( p = 0.009) in the nitazoxanide group (54 h; IQR 30—68.5)
and probiotics group (48 h; IQR 46—76) compared to the
control group (79 h; IQR 56—91.5).
The median duration of diarrhea since first dose for
nitazoxanide was shorter (26 h) than that for the probiotics
(41 h) but without statistical significance ( p = 0.14).
No significant differences between groups that could
have interfered in the final analysis were found with
respect to fever, vomiting, and number of stools per
day. Yellowish staining of physiologic fluids, characteristic
of nitazoxanide preparations, was the only adverse
Table 1 Clinical characteristics of the patients in the three study groups.
Control (n = 25) Nitazoxanide (n = 25) Probiotics (n = 25) p-Value
Age (months) 0.013a
Mean  SD 11  5.2 10  6.4 6.9  3.3
Median (IQR) 12 (7.5—13) 9 (4.5—15.5) 7 (4.5—8)
Sex, n (%) 0.42b
Male 12 (48) 16 (64) 12 (48)
Female 13 (52) 9 (36) 13 (52)
Nutrition status, n (%)
Normal 10 (40) 15 (60) 20 (80)
Mild malnutrition 10 (40) 5 (20) 2 (8)
Moderate malnutrition 5 (20) 5 (20) 3 (12)
Z score (median) 1.2 0.8 0.2 0.046a
Persistence of vomiting (% of patients)
Day 1 68 12 36 0.004b
Day 2 44 8 16 0.006b
Day 3 12 0 8 0.22b
Day 4 8 0 0 0.12b
Stool output (median  IQR)
Day 1 7 (6—10.5) 5 (4—9) 6 (4—11) 0.018a
Day 2 7 (4.5—10.5) 6 (3—8) 5 (3—12) 0.42a
Day 3 5 (2—9) 2 (1—5.5) 4 (0.5—6) 0.13a
Day 4 5 (0—5.5) 2 (0—4) 0 (0—3) 0.008a
SD, standard deviation; IQR, interquartile range.
a Wilcoxon test.
b Chi-square test.
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additional adverse effects in the probiotics or nitazoxanide
groups were observed by the investigators or nursing
staff.Table 2 Duration of fever, hospitalization, and diarrhea in the t
Control (n = 25) Nitazoxan
Duration of fever, hours
Mean  SD 24  20 22  25.6
Median (IQR) 18 (10—42.5) 15 (0—43)
Duration of hospitalization, hours
Mean  SD 100.9  27.3 81.8  30.
Median (IQR) 108 (77—119) 81 (61.5—
Duration of hospitalization from first dose, hours
Mean  SD 64.6  31.
Median (IQR) 63 (45.5—
Duration of diarrhea, hours
Mean  SD 74.6  26.6 52.9  27.
Median (IQR) 79 (56—91.5) 54 (30—68
Duration of diarrhea from first dose, hours
Mean  SD 35.6  28.
Median (IQR) 26 (12.5—
SD, standard deviation; IQR, interquartile range.
a Wilcoxon/Kruskal—Wallis Test; p-value for comparison of three gro
b Student’s t-test; p-value for comparison between nitazoxanide andSurvival analysis showed that the duration of diarrhea and
the duration of hospitalization were significantly shorter for
the nitazoxanide and probiotics groups than the control group
(p = 0.0113 and p = 0.0227, respectively; Figures 2 and 3).hree study groups.
ide (n = 25) Probiotics (n = 25) p-Value
24  27
20 (3—39) 0.51a
8 83  33.7
97) 72 (56—101) 0.017a
1 72.9  33.7
81) 69 (51—90.5) 0.34b
7 57.1  25.4
.5) 48 (36—76) 0.009a
9 47  25.7
49) 41 (27—65.5) 0.14b
ups.
probiotic.
Figure 3 Effect of nitazoxanide and probiotics on the duration
of hospitalization in comparison to the control group. Survival
analysis; p = 0.0227, Wilcoxon test.
Figure 2 Effect of nitazoxanide and probiotics on the duration
of diarrhea in comparison to the control group. Survival analysis;
p = 0.0113, Wilcoxon test.
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lowed-up after 48 h of discharge without signs of recurrence
of the diarrhea.
Discussion
The beneficial effects of probiotics and nitazoxanide were
confirmed in the current study. Both preparations decreased
the duration of diarrhea and hospitalization in comparison to
the control group. The difference between preparations was
also statistically significant in the final analysis. The median
duration of diarrhea from the first dose of nitazoxanide was
shorter (26 h) than that for the probiotics (41 h) but without
statistical significance ( p = 0.14). In a previous study con-
ducted in children, Rossignol et al. found similar results, with
shorter duration of diarrhea since first dose of administration
of nitazoxanide (31 h) in comparison to placebo (75 h) with
statistical significance ( p = 0.0137).9
The delay in diagnosis of the rotavirus infection is a
limitation of our study. The examination of stools was per-
formed during the first 8—24 h after admission, therefore
increasing the overall duration of hospitalization. It would
have been more reliable to include only patients admittedwith a previous diagnosis of rotavirus to omit this bias factor,
but the number of patients would have decreased signifi-
cantly.
The test used to detect rotavirus was not ideal. This
immunochromatographic test (RIDA Quick Rotavirus/Adeno-
virus Combi) has recently been evaluated, demonstrating low
sensitivity rates for rotavirus and adenovirus (75% and 22%,
respectively) and moderate specificity for adenovirus strains
(84%) in comparison with PCR.11 This was a limitation in our
study, resulting in the loss of patients for absence of disease
or the presence of adenovirus, and introducing a bias risk in
the studied patients.
According to the natural history of the disease, it is well
known that the duration of diarrhea secondary to rotavirus in
non-malnourished children is around 5—7 days.12,13 The dura-
tion of treatment with nitazoxanide is 3 days and for pro-
biotics is 5 days, hence in order to prevent any beneficial
effects being falsely attributed to the treatment used, we
included only patients with a history of diarrhea of less than
72 h before admission.
Zinc, vitamin A, probiotics, and immunoglobulins are
some of the products that have been studied for the treat-
ment of acute diarrhea and rotavirus gastroenteritis in chil-
dren. The effectiveness of zinc has been widely assessed,14—
16 and in fact The United Nations Children’s Fund (UNICEF)
and the World Health Organization (WHO) recommend a
course of treatment with oral zinc for 10—14 days in children
with acute diarrhea in developing countries.17 Vitamin A
supplementation does not significantly reduce the duration
of diarrhea in infants and children with acute diarrhea.
However, supplementation may have beneficial effects in
patients with malnourishment and persistent diarrhea.18—20
Immunoglobulin preparations have also been assessed in
pediatric patients, with findings of positive and negative
results according to the preparation used.21,22 There are
as yet no clear criteria for the use of these products in
rotavirus diarrhea.
Probiotics are currently available worldwide in different
preparations. As discussed previously, the effectiveness of
probiotics in acute diarrhea and rotavirus diarrhea has been
demonstrated in many controlled trials. Even though no
official recommendations exist for the use of these products
in acute diarrhea, prescriptions dispensed by pediatricians
are rapidly increasing around the world. The idea of restoring
ones normal intestinal flora and putting oneself back into
balance, without the use of drugs, makes these preparations
seem natural and safe.
In Latin America, nitazoxanide has been widely available
since the 1990s for use particularly in parasitic infections; it
ranges in cost from US$5 to US$9 per solution in Bolivia.
Probiotics are also available in different preparations with a
cost range of US$10 to US$15 for a 5-day treatment. The
difference in cost is important in developing countries where
the rate of incidence of severe rotavirus diarrhea is still high.
If we consider the reduction in the duration of diarrhea and
hospitalization, nitazoxanide becomes a good treatment
option for rotavirus diarrhea, being safe, relatively cheap,
and with good compliance to treatment from parents and
children.
The rotavirus vaccine has become the best tool to
decrease the mortality and morbidity associated with rota-
virus infections; many governmental immunization programs
Nitazoxanide vs. probiotics for acute rotavirus diarrhea 523have included this vaccine as part of their program, with
costs even lower than those of probiotics and nitazoxanide.
Newly-developed vaccines have been studied and proved
safe in many countries, showing good prevention rates for
severe cases of diarrhea secondary to rotavirus.23—25
Most developed countries and some Latin America coun-
tries, including Brazil, Ecuador, El Salvador, Panama, Vene-
zuela, and Nicaragua, have recently introduced the vaccine
into their programs; 26 however, these programs are not
available in the poorest countries like Bolivia. Epidemiologic
surveillance for rotavirus diarrhea has recently been intro-
duced in this country, with the expectation of introducing the
vaccine next year as part of the immunization program for all
infants.27 Nitazoxanide and probiotics become good alter-
natives in the management of hospitalized cases in areas
where rotavirus vaccines are not yet available and for those
who cannot be immunized or fail to build a proper immunity.
Although preliminary results have demonstrated the
effectiveness of nitazoxanide in comparison with probiotics
and the control group, we recommend that similar trials be
conducted with a larger number of patients in order to obtain
more reliable results with statistical significance. This will
enable criteria to be determined for its use.
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